Downloaded 18 times
Uploaded bySilja Chouquet
Biosimilars discussion on Twitter
The document summarizes findings from the Pharmasphere 2016 study which analyzed Twitter engagement of major pharmaceutical companies regarding biosimilars. It found that: 1) The biosimilars discussion on Twitter is not driven by pharmaceutical companies but by other stakeholders like media, services providers, and patient advocacy groups. 2) Mentions of pharmaceutical companies like Novartis and Amgen around biosimilars exploded in 2015 during regulatory approvals but companies were still not actively engaging in related discussions. 3) Media and services providers to the pharmaceutical industry retweeted and mentioned biosimilar topics on Twitter most frequently in 2015, indicating they are influential voices in related online conversations.
More Related Content
Similar to Biosimilars discussion on Twitter
Biosimilars discussion on Twitter
- 1. Pharmasphere 2016 Pharmasphere 2016 ExecutiveSummary Market research study and syndicated advisory service benchmarking how pharma companies engage via Twitter
- 2. Pharmasphere 2016 An analysisof primary corporate Twitter accounts with global audiences* 28 Top Pharma Companies 2 *Secondary accounts, including brand-specific and country-specific accounts, are excluded from this benchmark, but available upon request. @abbvie @actelion_com @abbottglobal @abbottnews @amgen @astrazeneca @bayer @bayerhealthcare @bmsnews @boehringer @celgene @gileadsciences @gsk @jnjnews @jnjglobalhealth @astellasus @lillypad @merck @mylannews @novartis @novonordisk @pfizer @sanofi @roche @takedaoncology@merckgroup @baxter_intl @biogen @allergan @ucb_news @shireplc new newnew new
- 3. Pharmasphere 2016 An analysisof leading biosimilar specialists and relevant big pharma competitors 23 Top Biosimilar Companies 3 *Secondary accounts, including brand-specific and country-specific accounts, are excluded from this benchmark, but available upon request. @alvogenpr @Alvotech_bio @AmgenBiosim @Bioconlimited @CelltrionDream @CreaBiomart @LFB_Group @stada @SunPharma_Live @ZydusUniverse @bioxpress @lillypad @merck @mylannews @sandoz_global @pfizer @tevapharm@merckgroup @Cipla_Global @drreddys @biocad_ltd @bmsnews @boehringer
- 4. Pharmasphere 2016 Pharma’s directaudience on Twitter consists of 730k unique accounts with a reach of almost 800 million 4 1.7 million Total follower relationships of tracked companies 730 k Unique followers of tracked companies On average users follow 2.3 companies Source: pharma follower analysis, 31.12.2015 total reach of pharma Twittersphere followers combined 791.7 million
- 5. Pharmasphere 2016 Biosimilars Twittersphere-Conversations and Influencers 5 The Biosimilars Twittersphere study analyzes the latest discussions on biosimilars, identifying critical topics and areas of interest from relevant stakeholder groups, subject matter experts, and their audiences. The research includes an assessment of pharma companies’ and emerging biosimilar specialists’ contributions to Twitter biosimilar conversations and recommendations for how pharma can engage with biosimilar stakeholders. Available August 2016
- 6. Pharmasphere 2016 The biosimilarsdiscussion on Twitter is not driven by pharma 6 499 biosimilar tweets* 1,709 Retweets of biosimilar tweets Original tweets Tweets retweeted Non-followers Followers 7,913 Direct mentions of pharma accounts Followers Non-followers Source: analysis of tweets, Jan 2015-Mar 2016
- 7. Pharmasphere 2016 Disease focusof biosimilar tweets grew and diversified CardiologyOncology Infectious diseases Neurology OtherPulmonaryImmunology Endocrinology * Sample of 31 global pharma accounts Source: ubercurious analysis of tweets during 12 months, Jan 2015-Dec 2015 7 2014 20152013
- 8. Pharmasphere 2016 Mentions explodedin 2015 with first US biosimilar approval Source: ubercurious analysis of tweets during 12 months, Jan 2015-Dec 2015 8 Tweets Retweets Mentions 2014 20152013 Novartis wins 1st US biosimilar approval for Zarxio; Amgen appeals Novartis wins appeal, Sandoz launches Zarxio Amgen starts communicating about biosimilars!!
- 9. Pharmasphere 2016 Novartis andAmgen most mentioned on Twitter in regards to biosimilars finally jumped in to communicate 9Source: analysis of tweets on 5 benchmark accounts, Jan 2015-Mar 2016 Ability to Retweet and mentions content key in creating engagement with relevant audiences, esp. MS patients Tweets, reteweets and mentions about biosimilars by pharma twitter accounts Tweets Retweets Mentions
- 10. Pharmasphere 2016 Methodology –Audience Segmentation 10 HCP Physicians, Nurses, Pharmacists, Healthcare Centers/Hospitals, Researchers Industry Pharma Companies, Trade Associations, Pharma Employees Media Medical and Science Publishers, Journalists, Conferences, Investors and Financial Publications Payor Insurers, Health Authorities, Politicians Advocacy Patient Groups, Public Health, Humanitarian General Public Non-health individuals and organizations Influe- holder ePatients, Health/Medicine Bloggers, Pharma Commentators Services Service providers to the pharmaceutical industry (CROs, agencies etc.) LowQual Insufficient information, spammers Twitter accounts are continuously segmented based on information in their twitter profiles as well as content tweeted. Accounts indicating more than one possible profession are attributed to most relevant segment from a pharma regulatory perspective e.g. a Physician and Blogger would be segmented as an Healthcare Professional (HCP).
- 11. Pharmasphere 2016 Media andServices retweeted and mentioned biosimilar topics on Twitter most in 2015 11Source: analysis of tweets on 5 benchmark accounts, Jan 2015-Mar 2016 Retweets and mentions received, segmented by stakeholder